Project
Abbvie M 14-347
Completed ยท 2015 until 2017
Borovicka Jan, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2015
End Date
2017
Financing
Industry
Study Design
Investigational Products: Adalimumab (40 mg/0.8 ml)
Doses: Open-Label Period
40 mg every other week or 40 mg ew for subjects whose disease is not
controlled on 40 mg eow beginning at Weeks 0 until Week 40
Mode of Administration: Subcutaneous (SC)
Duration of
Brief description/objective
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and
Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease